Physician profile
Michael J Schultz
NPI 1578560967
$1,893.52
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $92.57 · 2021: $50.00 · 2022: $54.77 · 2023: $1,280 · 2024: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $722 · Food and Beverage: $688 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $722.04 |
| Food and Beverage | $688.43 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $1,123.77 | 2023-2024 | Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector |
| Genentech USA, INC. | $260.80 | 2019-2023 | Phesgo |
| Puma Biotechnology, INC. | $143.30 | 2019-2020 | |
| Abiomed | $132.46 | 2023 | Impella |
| Abbvie INC. | $77.01 | 2023-2024 | Natrelle Saline-Filled Breast Implants |
| Mentor Worldwide LLC | $33.05 | 2021-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Allergan, INC. | $27.65 | 2022 | |
| Stryker Corporation | $27.12 | 2022 | |
| Ethicon US, LLC | $24.01 | 2023 | Vistaseal |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Keytruda |
| Baxter Healthcare | $14.34 | 2023 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.